In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Protara Therapeutics (TARA – Research ...
LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...
Analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Zymeworks in a research note issued to investors on ...
Stock analysts at Lifesci Capital cut their FY2025 earnings per share estimates for Astria Therapeutics in a research report ...
5d
Fintel on MSNLifeSci Capital Initiates Coverage of Immunome (IMNM) with Outperform RecommendationFintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Immunome (NasdaqCM:IMNM) with a Outperform ...
5d
Fintel on MSNLifeSci Capital Initiates Coverage of Molecular Partners AG - Depositary Receipt () (MOLN) with Outperform RecommendationFintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Molecular Partners AG - Depositary Receipt () ...
Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Protara Therapeutics (NasdaqGM:TARA) with a Outperform recommendation. As of March 4, 2025, the average one-year price ...
The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. The Index seeks to track the ...
Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Molecular Partners AG - Depositary Receipt () (NasdaqGS:MOLN) with a Outperform recommendation. As of March 4 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results